Stay updated on Birinapant and Pembrolizumab in Solid Tumors Clinical Trial
Sign up to get notified when there's something new on the Birinapant and Pembrolizumab in Solid Tumors Clinical Trial page.

Latest updates to the Birinapant and Pembrolizumab in Solid Tumors Clinical Trial page
- Check4 days agoNo Change Detected
- Check11 days agoChange DetectedThe revision label updated from v3.4.1 to v3.4.2.SummaryDifference0.1%

- Check18 days agoChange DetectedRevision: v3.4.1 is now displayed, replacing v3.4.0 as the page revision. This is a minor metadata update with no changes to study content or functionality. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check19 days agoChange DetectedOnly a minor revision update from v3.4.0 to v3.4.1 is shown, with no visible changes to core content or functionality. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check27 days agoChange DetectedThe changes are minor UI/metadata updates: a glossary display was added and QC/versioning labels (Last Update Submitted that Met QC Criteria, No FEAR Act Data, Revision: v3.4.0) were updated, replacing previous lowercase/case variants. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check41 days agoChange DetectedRevision updated from v3.3.3 to v3.3.4; no study content or functionality changes. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check62 days agoChange DetectedThe Locations section is reorganized under a single 'Locations' header listing states (Arizona, California, Florida, Maryland, Massachusetts, Pennsylvania, Texas). The discrete location entries (Arizona Locations, California Locations, Florida Locations, Maryland Locations, Massachusetts Locations, Pennsylvania Locations, Texas Locations) were removed, a 'Revision: v3.3.3' tag was added, and the 'HHS Vulnerability Disclosure' link was removed.SummaryDifference0.8%

Stay in the know with updates to Birinapant and Pembrolizumab in Solid Tumors Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Birinapant and Pembrolizumab in Solid Tumors Clinical Trial page.